Skip to content
DataLookout
Menu

Sun Yat-sen University clinical trial pipeline

Get alerts when Sun Yat-sen University's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19

What changed in the last 30 days

20 trials changed in the last 30 days: 1 stopped, 6 with notable changes, 13 with minor changes only.

  1. Minor: Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI Enrollment closed, study ongoing Sun Yat-sen UniversityPhase 3 NCT06545747
  2. Minor: 8 trials marked Unknown by the registry's verification sweep Changed Registry verification sweep8 trials
    1. Minor: TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting Sun Yat-sen UniversityPhase 3 NCT06664983
    2. Minor: Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) Changed Registry marked status Unknown (sponsor has not verified the record since Feb 2022); last known: Recruiting Sun Yat-sen UniversityPhase 3 NCT05044117
    3. Minor: Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting Sun Yat-sen UniversityPhase 2 NCT06592612
    4. Minor: Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting Sun Yat-sen UniversityPhase 2 NCT05468242
    5. Minor: NPBC · Nomogram for Predicting Biliary Complication Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting Sun Yat-sen UniversityNot specified NCT06658665
    6. Minor: GOS and the Management of Hyperuricemia Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting Sun Yat-sen UniversityNot applicable NCT06630377
    7. Minor: Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting Sun Yat-sen UniversityNot applicable NCT06624098
    8. Minor: Posterior Continuous Curvilinear Capsulorhexis With or Without Anterior Vitrectomy Changed Registry marked status Unknown (sponsor has not verified the record since Nov 2021); last known: Recruiting Sun Yat-sen UniversityNot applicable NCT05136209
  3. Notable: PHM · IOP Lowering on Progressive HM Primary endpoint(s) modified Sun Yat-sen UniversityNot applicable NCT05850936
  4. Minor: Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy · Locally Advanced Pancreatic Cancer (SAGE) Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2023); last known: Not Yet Recruiting Sun Yat-sen UniversityPhase 2 NCT05988372
  5. Notable: BCIRT-01 · Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation Primary completion pushed from Dec 31, 2025 to Dec 31, 2026 Sun Yat-sen UniversityPhase 2 NCT05975307
  6. Notable: Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis · Nasopharyngeal Carcinoma Recruitment opened Sun Yat-sen UniversityPhase 2 NCT07567742
  7. Notable: Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal Carcinoma Enrollment reduced: 514 → 298 participants Sun Yat-sen UniversityPhase 2 NCT07524413
  8. Notable: ACTION-001 · TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk Recruitment opened Sun Yat-sen UniversityPhase 2 NCT07487662
  9. Minor: 2 trials marked Unknown by the registry's verification sweep Changed Registry verification sweep2 trials
    1. Minor: Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer Changed Registry marked status Unknown (sponsor has not verified the record since Jan 2023); last known: Active, Not Recruiting Sun Yat-sen UniversityPhase 2 NCT04304209
    2. Minor: Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents Changed Registry marked status Unknown (sponsor has not verified the record since Jan 2023); last known: Recruiting Sun Yat-sen UniversityNot applicable NCT05718492
  10. Notable: Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma Primary and study completion dates pushed to Dec 30, 2026 Sun Yat-sen UniversityNot specified NCT06644430
  11. Minor: Failure of Immunotherapy With Vorolanib Combined With Everolimus Interventions modified Sun Yat-sen UniversityPhase 2 NCT06730672
  12. Stopped: Validation of Insulin Dose Prediction Model Based on Artificial Intelligence Algorithm Trial terminated Sun Yat-sen UniversityNot applicable NCT07066891
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-11-16 NCT07938619 Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or… Phase 2 Not Yet Recruiting
2026-11-13 NCT07934927 A Phase II Study of Nab-Paclitaxel Combined With Retlirafusp Alfa and Apatinib in… Phase 2 Recruiting
2026-11-10 NCT07927452 Anatomic Versus Nonanatomic Liver Resection After Conversion Therapy for Hepatocellular… Recruiting
2026-11-09 NCT07926672 Artificial Intelligence-Assisted Imaging for Diagnosis and Management of Focal Liver… Recruiting
2026-11-06 NCT07922915 Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell… Phase 2 Not Yet Recruiting
2026-11-06 NCT07922928 Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney… Phase 2 Not Yet Recruiting
2026-11-04 NCT07915258 Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Head and Neck Squamous Cell… Phase 2 Not Yet Recruiting
2026-11-04 NCT07915271 Performance of Multi-Cancer Detection Test in Asymptomatic Patients With Neoplastic… Not Yet Recruiting
2026-10-29 NCT07902713 Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic… Phase 2 Not Yet Recruiting
2026-10-29 NCT07904156 A Phase III Randomized Controlled Trial of Serplulimab Plus Fruquintinib as Adjuvant… Phase 3 Not Yet Recruiting

Active trials by phase

Early Phase 1
2
Phase 1
12
Phase 1/2
20
Phase 2
243
Phase 2/3
12
Phase 3
101
Phase 4
3
Not charted: 162 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 43

Get alerts when Sun Yat-sen University's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free